PharmAla Incorporates Australian Entity for Clinical Research

Core Insights - PharmAla Biotech Holdings Inc. has established a wholly-owned subsidiary, PharmAla Biotech Australia Pty Ltd., to conduct research and development activities in Australia [1][2] - The Australian market is recognized for its strong biotech development environment, which the company aims to leverage through existing relationships and expertise [2] - PharmAla Australia will hold a full and perpetual license to the ALA-002 asset and associated patents, enabling it to engage in manufacturing development and clinical research [2][3] Company Developments - The company appointed Dr. Evan Lewis to its Scientific Advisory Board, effective September 1, 2025, enhancing its expertise in clinical research and drug discovery [3][4] - Dr. Lewis has a background in neurology, particularly in epilepsy and pediatric neurology, and has previously led initiatives in psychedelic neurology and medical cannabis [4][5] - PharmAla is focused on alleviating the backlog of clinical-grade MDMA and developing novel drugs within the MDXX class, positioning itself as a leader in the psychedelics industry [6] Industry Context - Australia is highlighted as having a favorable regulatory environment for launching clinical trials, which is expected to benefit PharmAla's operations [3] - The company aims to capitalize on the growing ecosystem of biotech financiers and government incentives in Australia [3] - PharmAla is currently the only company providing clinical-grade MDMA for patient treatments outside of clinical trials, indicating a unique market position [6]